High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer

American Journal of Clinical Pathology

Volumn 130, Issue 2, 2008, Pages 247-253

  Simi, Lisa ^a   Pratesi, Nicola ^a   Vignoli, Marina ^a   Sestini, Roberta ^a   Cianchi, Fabio ^a   Valanzano, Rosa ^a   Nobili, Stefania ^a   Mini, Enrico ^a   Pazzagli, Mario ^a   Orlando, Claudio ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dept of Clinical Physiopathology ^*  (Italy)

Author keywords

Colon cancer; Oncogenes; Somatic mutations

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BRAF GENE; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; KRAS GENE; MALE; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 48649092117     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LWDY1AXHXUULNVHQ     Document Type: Article

References (39)

1. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics. 2007;8:597-608.
2. Wittwer CT, Reed GH, Gundry CN, et al. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003;49:853-860.
3. Liew M, Pryor R, Palais R, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004;50:1156-1164.
4. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004;50:1748-1754.
5. Graham R, Liew M, Meadows C, et al. Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem. 2005;51:1295-1298.
6. Kennerson ML, Warburton T, Nelis E, et al. Mutation scanning the GJB1 gene with high-resolution melting analysis: implications for mutation scanning of genes for Charcot-Marie-Tooth disease. Clin Chem. 2007;53:349-352.
7. Margraf RL, Mao R, Highsmith WE, et al. RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis. J Mol Diagn. 2007;9:184-196.
8. Pal T, Napierala D, Becker TA, et al. The presence of germ line mosaicism in cleidocranial dysplasia. Clin Genet. 2007;71:589-591.
9. Dobrowolski SF, Ellingson CE, Caldovic L, et al. Streamlined assessment of gene variants by high resolution melt profiling utilizing the ornithine transcarbamylase gene as a model system. Hum Mutat. 2007;28:1133-1140.
10. Krypuy M, Ahmed AA, Etemadmoghadam D, et al. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer. 2007;7:168. doi:10.1186/1471-2407-7-168.
11. Takano T, Ohe Y, Tsuta K, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res. 2007;13(8 pt 1):5385-5390.
12. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
13. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13:2890-2896.
14. Shibata T, Hanada S, Kokubu A, et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci. 2007;98:985-991.
15. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295. doi:10.1186/1471-2407-6-295.
16. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26:158-163.
17. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007;104:18654-18659.
18. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934. doi: 10.1038/418934a.
19. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289-305.
20. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol. 2007;212:124-133.
21. Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 2007;67:3551-3554.
22. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;10:2. doi:10.1186/1476-4598-5-2.
23. Willmore-Payne C, Holden JA, Tripp S, et al. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005;36:486-493.
24. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94:455-459.
25. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18:77-82.
26. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007;104:5569-5574.
27. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;23:554. doi: 10.1126/science.1096502.
28. Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer. 2007;121:1771-1778.
29. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103:1475-1479.
30. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562-4567.
31. Jass JR, Sobin LH. Histological Typing of Intestinal Tumors. 2nd ed. Berlin, Germany: Springer-Verlag; 1989. International Histological Classification of Tumors.
32. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;6:1420-1425.
33. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006;5:2606-2612.
34. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386. Source code available at http://fokker.wi.mit.edu/primer3/. Accessed January 2007.
35. Akagi K, Uchibori R, Yamaguchi K, et al. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun. 2007;352:728-732.
36. Bollag G, Adler F, elMasry N, et al. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem. 1996;271:32491-32494.
37. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113-130.
38. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-351.
39. Klockow B, Ahmadian MR, Block C, et al. Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling. Oncogene. 2000;19:5367-5376.